However, in the tumor microenvironment, antigen presentation by tumor cells is less potent than presentation by professional antigen-presenting cells (45): under those circumstances, reduced CD5 levels could enhance TCR recognition to tumor epitopes and enhance T cell activation and anti-tumor activity. The gene discussed is CD5; the disease is neoplasm.